Patient characteristics
| . | Training . | Validation . | P values . |
|---|---|---|---|
| n = 1306 . | n = 557 . | ||
| Median age at HCT, y (range) | 56 (0, 79) | 54 (0, 79) | .206 |
| Recipient age, category | |||
| <18 | 146 (11.2) | 83 (14.9) | .077 |
| 18-54 | 474 (36.3) | 199 (35.7) | |
| ≥55 | 686 (52.5) | 275 (49.4) | |
| Sex mismatch | |||
| Female to male | 219 (16.8) | 103 (18.6) | .349 |
| Other | 1087 (83.2) | 452 (81.4) | |
| Race | |||
| White | 1108 (84.8) | 462 (82.9) | .362 |
| Black | 70 (5.4) | 25 (4.5) | |
| Asian | 46 (3.5) | 25 (4.5) | |
| Others | 6 (0.5) | 5 (0.9) | |
| Unknown | 76 (5.8) | 40 (7.2) | |
| Primary disease | |||
| Acute leukemia | 677 (51.8) | 299 (53.7) | .349 |
| MDS/MPN | 341 (26.1) | 147 (26.4) | |
| Malignant lymphoma | 117 (9.0) | 36 (6.5) | |
| Other | 171 (13.1) | 75 (13.5) | |
| Disease risk | |||
| Standard | 1059 (81.1) | 430 (77.2) | .058 |
| High | 247 (18.9) | 127 (22.8) | |
| Donor type | |||
| HLA matched related | 267 (20.4) | 111 (19.9) | .058 |
| HLA matched unrelated | 714 (54.7) | 277 (49.7) | |
| HLA mismatched related | 8 (0.6) | 4 (0.7) | |
| HLA mismatched unrelated | 122 (9.3) | 65 (11.7) | |
| Haploidentical | 148 (11.3) | 65 (11.7) | |
| Umbilical cord blood | 47 (3.6) | 35 (6.3) | |
| GVHD prophylaxis | |||
| CNI and MTX based | 691 (52.9) | 292 (52.4) | .744 |
| CNI and MMF based | 305 (23.4) | 143 (25.7) | |
| PTCy | 219 (16.8) | 82 (14.7) | |
| Ex vivo T-cell depletion | 38 (2.9) | 17 (3.1) | |
| Other | 53 (4.1) | 23 (4.1) | |
| HCT-CI | |||
| 0-2 | 884 (67.7) | 372 (66.8) | .706 |
| ≥3 | 422 (32.3) | 185 (33.2) | |
| In vivo T-cell depletion | |||
| No | 809 (61.9) | 341 (61.2) | .795 |
| Yes | 497 (38.1) | 216 (38.8) | |
| Donor source | |||
| Bone marrow | 252 (19.3) | 117 (21.0) | .020 |
| Peripheral blood | 1007 (77.1) | 405 (72.7) | |
| Umbilical cord blood | 47 (3.6) | 35 (6.3) | |
| Conditioning | |||
| MAC (TBI <8 Gy) | 532 (40.7) | 226 (40.6) | .923 |
| MAC (TBI ≥8 Gy) | 204 (15.6) | 91 (16.3) | |
| RIC | 570 (43.6) | 240 (43.1) | |
| Sample available at Tx | |||
| No | 256 (19.6) | 125 (22.4) | .168 |
| Yes | 1050 (80.4) | 432 (77.6) | |
| Median y of HCT (range) | 2018 (2014-2021) | 2017 (2014-2021) | .117 |
| . | Training . | Validation . | P values . |
|---|---|---|---|
| n = 1306 . | n = 557 . | ||
| Median age at HCT, y (range) | 56 (0, 79) | 54 (0, 79) | .206 |
| Recipient age, category | |||
| <18 | 146 (11.2) | 83 (14.9) | .077 |
| 18-54 | 474 (36.3) | 199 (35.7) | |
| ≥55 | 686 (52.5) | 275 (49.4) | |
| Sex mismatch | |||
| Female to male | 219 (16.8) | 103 (18.6) | .349 |
| Other | 1087 (83.2) | 452 (81.4) | |
| Race | |||
| White | 1108 (84.8) | 462 (82.9) | .362 |
| Black | 70 (5.4) | 25 (4.5) | |
| Asian | 46 (3.5) | 25 (4.5) | |
| Others | 6 (0.5) | 5 (0.9) | |
| Unknown | 76 (5.8) | 40 (7.2) | |
| Primary disease | |||
| Acute leukemia | 677 (51.8) | 299 (53.7) | .349 |
| MDS/MPN | 341 (26.1) | 147 (26.4) | |
| Malignant lymphoma | 117 (9.0) | 36 (6.5) | |
| Other | 171 (13.1) | 75 (13.5) | |
| Disease risk | |||
| Standard | 1059 (81.1) | 430 (77.2) | .058 |
| High | 247 (18.9) | 127 (22.8) | |
| Donor type | |||
| HLA matched related | 267 (20.4) | 111 (19.9) | .058 |
| HLA matched unrelated | 714 (54.7) | 277 (49.7) | |
| HLA mismatched related | 8 (0.6) | 4 (0.7) | |
| HLA mismatched unrelated | 122 (9.3) | 65 (11.7) | |
| Haploidentical | 148 (11.3) | 65 (11.7) | |
| Umbilical cord blood | 47 (3.6) | 35 (6.3) | |
| GVHD prophylaxis | |||
| CNI and MTX based | 691 (52.9) | 292 (52.4) | .744 |
| CNI and MMF based | 305 (23.4) | 143 (25.7) | |
| PTCy | 219 (16.8) | 82 (14.7) | |
| Ex vivo T-cell depletion | 38 (2.9) | 17 (3.1) | |
| Other | 53 (4.1) | 23 (4.1) | |
| HCT-CI | |||
| 0-2 | 884 (67.7) | 372 (66.8) | .706 |
| ≥3 | 422 (32.3) | 185 (33.2) | |
| In vivo T-cell depletion | |||
| No | 809 (61.9) | 341 (61.2) | .795 |
| Yes | 497 (38.1) | 216 (38.8) | |
| Donor source | |||
| Bone marrow | 252 (19.3) | 117 (21.0) | .020 |
| Peripheral blood | 1007 (77.1) | 405 (72.7) | |
| Umbilical cord blood | 47 (3.6) | 35 (6.3) | |
| Conditioning | |||
| MAC (TBI <8 Gy) | 532 (40.7) | 226 (40.6) | .923 |
| MAC (TBI ≥8 Gy) | 204 (15.6) | 91 (16.3) | |
| RIC | 570 (43.6) | 240 (43.1) | |
| Sample available at Tx | |||
| No | 256 (19.6) | 125 (22.4) | .168 |
| Yes | 1050 (80.4) | 432 (77.6) | |
| Median y of HCT (range) | 2018 (2014-2021) | 2017 (2014-2021) | .117 |
CNI, calcineurin inhibitor; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; MAC, myeloablative conditioning; MDS/MPN, myelodysplastic syndromes/myeloproliferative neoplasms; MMF, mycophenolate mofetil; MTX, methotrexate; PTCy, posttransplant cyclophosphamide; RIC, reduced-intensity conditioning; TBI, total body irradiation; Tx, treatment.